ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Population PK/PD of Propofol in the Morbidly Obese Patient

This study is not yet open for participant recruitment.
Verified by St. Antonius Hospital, November 2006

Sponsored by: St. Antonius Hospital
Information provided by: St. Antonius Hospital
ClinicalTrials.gov Identifier: NCT00395681
  Purpose

Rationale: The extreme increase of obesity in the last years had led to this study. There is no consensus about how to anaesthetise morbidly obese patients. The amounts of narcotics given vary widely and rather depend on the anaesthetist than on the pharmacokinetics and dynamics in the morbidly obese patient. Reason for this is that it is not clear in what extend the pharmacokinetics and dynamics are affected in the morbidly obese patient.

Objective: The study is performed in order to develop a population pharmacokinetic and pharmacodynamic model of Propofol when used for induction and maintenance of anaesthesia in the morbidly obese patient (BMI > 40). A covariate analysis will be performed in order to account for variability in pharmacokinetic and/or pharmacodynamic parameters. This model will take into account patient and procedure bound covariates. The results will be used to develop individualised dosing schemes of Propofol when used for induction and maintenance of anaesthesia in morbidly obese patients.

Study design: A randomised, therapeutic and non-invasive study.

Study population: Morbidly obese patients with a Body Mass Index > 40 undergoing laparoscopic banding or gastric bypass surgery, 18-60 year old.

Intervention (if applicable): Patients will be randomised into two groups, one group will be given 200 milligrams of Propofol and the other group will be given 350 milligrams of Propofol. During the induction of anaesthesia with Propofol over 60 seconds, the patient is asked to count in order to measure time to induction of anaesthesia. During and following anaesthesia a maximum of 50 ml of blood will be taken from an indwelling arterial line. Depth of sedation will be measured using non-invasive Bispectral Index (target 40-60) and other standard measures (heart frequency and blood pressure).

Main study parameters/endpoints: Primary endpoints: pharmacokinetic parameters; clearance, intercompartmental clearance, volume of central compartment and volume of peripheral compartment.

Secondary endpoints: pharmacodynamic parameters; time to induction of anaesthesia (stop counting, eyelash reflex, quality of anaesthesia, corresponding dose required for induction of anaesthesia for both induction doses), EC50 using BIS, required doses of Propofol during maintenance of anaesthesia, wake-up time.

Nature and extent of the burden and risks associated with participation benefit and group relatedness: A maximum amount of 50 milliliters of blood will be sampled from an indwelling arterial line. The patient will be asked to count slowly during induction of anaesthesia. Both induction doses of 200 and 350 milligrams are currently used standard induction doses for morbidly obese patients.


Condition Phase
Morbid Obesity
Phase IV

MedlinePlus related topics:   Anesthesia    Obesity   

ChemIDplus related topics:   Propofol   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Natural History, Cross-Sectional, Defined Population, Prospective Study
Official Title:   Population Pharmacokinetics and Pharmacodynamics of Propofol in the Morbidly Obese Patient

Further study details as provided by St. Antonius Hospital:

Estimated Enrollment:   20
Study Start Date:   January 2007

Show detailed description  Show Detailed Description

  Eligibility
Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Patients with a Body Mass Index > 40 undergoing laparoscopic banding or gastric bypass surgery.

Exclusion Criteria:

  • Epilepsy, pregnancy, breastfeeding and known allergy for Propofol, egg lecithin or soy bean oil.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00395681

Contacts
Contact: Simone van Kralingen, resident     +31641254454     svankralingen@hotmail.com    

Locations
Netherlands, Utrecht
St. Antonius Hospital     Not yet recruiting
      Nieuwegein, Utrecht, Netherlands, 3430 EM

Sponsors and Collaborators
St. Antonius Hospital

Investigators
Principal Investigator:     Simone van Kralingen, resident     St. Antonius Ziekenhuis    
  More Information


Study ID Numbers:   13980
First Received:   November 1, 2006
Last Updated:   November 1, 2006
ClinicalTrials.gov Identifier:   NCT00395681
Health Authority:   Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by St. Antonius Hospital:
Obesity  
Propofol  
Morbidly obese  
BMI  

Study placed in the following topic categories:
Body Weight
Signs and Symptoms
Obesity
Nutrition Disorders
Overweight
Overnutrition
Obesity, Morbid
Propofol

Additional relevant MeSH terms:
Anesthetics, Intravenous
Anesthetics, General
Therapeutic Uses
Hypnotics and Sedatives
Physiological Effects of Drugs
Central Nervous System Depressants
Anesthetics
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 23, 2008




Links to all studies - primarily for crawlers